Transdermal Microneedle Nanotransfersomes: Advancing Risedronate Sodium Delivery for Osteoporosis Treatment

Study Background and Research Question

Osteoporosis remains a progressive skeletal disorder characterized by declining bone mass and microarchitectural deterioration, culminating in an increased risk of fragility fractures and associated morbidity. While oral bisphosphonates such as Risedronate Sodium are established anti-resorptive agents, their clinical utility is constrained by poor oral bioavailability (<1%), gastrointestinal intolerance, and the need for long-term adherence. The referenced study (Sultana et al., 2023) investigates whether a dissolving microneedle (MN) patch, loaded with Risedronate Sodium and Ursolic acid bipartite nanotransfersomes (RU-NTRs), can overcome these limitations and provide a more effective transdermal therapy for osteoporosis.

Key Innovation from the Reference Study

The central innovation of this research is the design and optimization of a gelatin-based dissolving microneedle patch incorporating both Risedronate Sodium, a potent FPP synthase inhibitor, and Ursolic acid, a natural triterpenoid with bone-protective properties. By encapsulating these agents in nanotransfersomes—a class of ultradeformable vesicular carriers—the study addresses both the permeability challenges of transdermal delivery and the sustained release necessary for effective anti-resorptive therapy. This dual-drug, bipartite nanocarrier approach is positioned to synergistically modulate bone metabolism, leveraging both osteoclast-mediated bone resorption inhibition (via Risedronate) and osteoblast-stimulating effects (via Ursolic acid).

Methods and Experimental Design Insights

The research employs a systematic Central Composite Design to optimize three key formulation parameters: phospholipid concentration, surfactant concentration, and sonication time. These factors were selected for their influence on vesicle size, entrapment efficiency, and polydispersity index (PDI)—critical determinants of nanotransfersome performance. The optimized RU-NTR formulation achieved vesicle sizes averaging 271.9 ± 8.45 nm, with narrow size distribution (PDI 0.184 ± 0.01) and high entrapment efficiencies for both Risedronate Sodium (86.12 ± 5.20%) and Ursolic acid (85.65 ± 4.88%).

The microneedle arrays were fabricated using gelatin, yielding patches with robust mechanical strength, high folding endurance, and uniform drug content (98.68 ± 0.004%). In vitro release studies demonstrated a sustained profile for both drugs, while ex vivo permeation tests (using skin models) indicated up to 80% drug permeation within 24 hours—a marked improvement compared to conventional topical or oral administration. Confocal laser scanning microscopy (CLSM) confirmed effective skin penetration of the RU-NTRs delivered via the dissolving MN system (Sultana et al., 2023).

Protocol Parameters

• Nanotransfersome composition optimization: Use Central Composite Design to vary phospholipid (e.g., 80–120 mg), surfactant (e.g., 10–30 mg), and sonication time (e.g., 5–15 min) to maximize vesicle entrapment and minimize PDI.
• Microneedle patch fabrication: Employ gelatin as the matrix; cast into microneedle molds and dry under controlled humidity to achieve patches with high folding endurance and mechanical strength.
• In vitro release: Use Franz diffusion cells with appropriate membranes; monitor cumulative drug release over 24 hours to confirm sustained delivery (target: ~75–80% release for both agents).
• Ex vivo permeation: Utilize excised animal skin or equivalent models; quantify drug permeation using HPLC or LC-MS/MS at multiple timepoints.
• CLSM skin penetration studies: Label nanotransfersomes with fluorescent marker and visualize penetration depth post-application of MN patch.

Core Findings and Why They Matter

The study demonstrates that the dissolving MN patch system achieves several critical advancements over traditional oral bisphosphonate therapy:

• Enhanced bioavailability: Transdermal delivery circumvents the gastrointestinal tract, mitigating the low (<1%) oral absorption associated with Risedronate Sodium (Sultana et al., 2023).
• Sustained, controlled drug release: The nanotransfersome formulation provides a gradual release profile, which is advantageous for maintaining therapeutic plasma concentrations and minimizing dosing frequency.
• High entrapment and permeation efficiency: Entrapment efficiencies above 85% and up to 80% permeation within 24 hours suggest effective drug utilization and delivery across the skin barrier.
• Synergistic dual-drug strategy: Co-delivery of Risedronate Sodium and Ursolic acid targets both osteoclast and osteoblast pathways, potentially offering superior bone-protective effects compared to monotherapy.

These findings are significant for the field of bone metabolism research and may inform the development of next-generation bisphosphonate delivery systems with improved patient adherence, reduced side effects, and enhanced clinical efficacy.

Comparison with Existing Internal Articles

Several internal reviews have detailed Risedronate Sodium’s role as a bisphosphonate inhibitor of bone resorption and a versatile FPP synthase inhibitor for both osteoporosis and cancer research. However, the microneedle patch nanotransfersome approach described by Sultana et al. represents a novel translational leap by overcoming bioavailability and compliance barriers associated with oral or injectable bisphosphonates. Additionally, the exploration of inhaled or nano-formulations in other recent work aligns with this study’s paradigm of innovative, non-oral bisphosphonate delivery. Collectively, these resources underscore a growing trend toward advanced delivery platforms for both bone and respiratory disease models.

Limitations and Transferability

While the microneedle patch system exhibits promising in vitro and ex vivo performance, some limitations remain:

• Translational gap: Efficacy and safety in human clinical settings remain to be established.
• Skin variability: Differences in skin structure between animal models and humans may impact permeation rates.
• Device scalability: Large-scale manufacturing and long-term stability of the patches require further validation.

Nonetheless, the principles and workflow established in this study are broadly transferable to other hydrophilic, low-bioavailability agents—including those used as antiproliferative agents in tumor cell lines or for respiratory indications—where transdermal or nano-enabled delivery may offer significant advantages.

Research Support Resources

To facilitate similar experimental workflows, researchers can source Risedronate Sodium (SKU A5293) from APExBIO, which is suitable for in vitro and in vivo studies involving bone metabolism, antiproliferative research, and advanced delivery system development. The compound’s physicochemical properties and established protocols support its use in both conventional and innovative formulations. For further technical details and comparative protocol insights, see this protocol-focused review.